Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Template:SUIT-010"

From Bioblast
Line 27: Line 27:


|-
|-
| 3U
| ce4D
| [[PM]]<sub>''E''</sub>
| [[S]]<sub>''P''</sub>
| [[N]]
| [[S]]
| CI
| CII
| 1PM;2D;3U
| ce1;ce2Rot;ce3S;ce4D


{{Template:SUIT N}} {{Template:SUIT U*}}
{{Template:SUIT S}} {{Template:SUIT OXPHOS}}


|-
|-
| 4G
| 1Dig
| [[PGM]](E)
| [[S]]<sub>''P''</sub>
| [[N]]
| [[S]]
| CI
| CII
| 1PM;2D;3U;4G
| ce1;ce2Rot;ce3S;ce4D;1Dig
 
{{Template:SUIT N}} {{Template:SUIT ET}}
 
|-
| 5S
| [[PGMS]]<sub>''E''</sub>
| [[NS]]
| CI<small>&</small>II
| 1PM;2D;3U;4G;5S
 
{{Template:SUIT N}} & {{Template:SUIT S}} {{Template:SUIT NS}} {{Template:SUIT ET}}
 
|-
| 6Oct
| [[OctPGMS]]<sub>''E''</sub>
| [[FNS]]
| FAO<small>&</small>CI<small>&</small>II
| 1PM;2D;3U;4G;5S;6Oct


{{Template:SUIT FNS}} {{Template:SUIT ET}}
{{Template:SUIT S}} {{Template:SUIT Digitonin titration}} {{Template:SUIT OXPHOS}}  


|-
|-
| 7Rot
| 1c
| [[S]]<sub>''E''</sub>
| [[S]]<sub>''P''</sub>
| [[S]]
| [[S]]
| CII
| CII
| 1PM;2D;3U;4G;5S;6Oct;7Rot
| ce1;ce2Rot;ce3S;ce4D;1Dig;1c
 
{{Template:SUIT Rot}} {{Template:SUIT ET}}
 
|-
| 8Gp
| [[SGp]](E)
| [[SGp]]
| CII<small>&</small>GpDH
| 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp
 
{{Template:SUIT SGp}} {{Template:SUIT ET}}


|-
{{Template:SUIT S}} {{Template:SUIT c}} {{Template:SUIT OXPHOS}}  
| 9Ama
| [[ROX]]
|
| 
| {{Template:SUIT Ama}}


|}
|}
{{Template:SUIT CIV}}
{{Template:Keywords in SUIT protocols}}

Revision as of 09:55, 15 January 2019

MitoPedia: SUIT

Steps and respiratory states

SUIT-010

Template:ROUTINE

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
ce2Rot ROX CII ce1;ce2Rot

Succinate pathway control state (S-pathway) after inhibiting CI with rotenone, which also inhibits the F-pathway.

ce3S SL S CII ce1;ce2Rot;ce3S

Succinate, S ( type S-pathway to Q). Template:SUIT LEAK

ce4D SP S CII ce1;ce2Rot;ce3S;ce4D

Succinate, S ( type S-pathway to Q). OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

1Dig SP S CII ce1;ce2Rot;ce3S;ce4D;1Dig

Succinate, S ( type S-pathway to Q). Template:SUIT Digitonin titration OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

1c SP S CII ce1;ce2Rot;ce3S;ce4D;1Dig;1c

Succinate, S ( type S-pathway to Q). Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]). OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

Retrieved from "https://wiki.oroboros.at/index.php?title=Template:SUIT-010&oldid=169402"
Powered by MediaWiki
Powered by Semantic MediaWiki